Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지

Development of Angiogenesis Inhibitors: an Analysis of the Patent Literatures

  • Sohn, Eun-Soo (Division of Information Analysis, Korea Institute of Science and Technology Information (KISTI)) ;
  • Sohn, Eun-Hwa (Department of Herbal Medicine Resource, Kangwon National University)
  • Received : 2011.06.15
  • Accepted : 2011.06.21
  • Published : 2011.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The development of a general appreciation for the central role of angiogenesis in cancer growth and metastasis and other disease status has led to a wide range of new therapeutic strategies. This paper reviews the domestic and international trends through technology, marketing and patent information analysis dealing with anti-angiogenic agents. This analytical research has led to the identification of new targets associated with angiogenesis, leading to the development of an extensive number of preclinical screening of antiangiogenetic agents.

Keywords

References

  1. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 2003. 63: 8890-8898.
  2. Abou-Nassar K, Brown JR. Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2010. 8: 886-895.
  3. Brack SS, Dinkelborg LM, Neri D. Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging. 2004. 31: 1327-1341.
  4. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000. 60: 1388-1393.
  5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971. 285: 1182-1186. https://doi.org/10.1056/NEJM197111182852108
  6. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007. 6: 273-286. https://doi.org/10.1038/nrd2115
  7. Hayden EC. Cutting off cancer's supply lines. Nature. 2009. 458: 686-687. https://doi.org/10.1038/458686b
  8. Jung YD, Ahmad SA, Akagi Y, Takahashi Y, Liu W, Reinmuth N, Shaheen RM, Fan F, Ellis LM. Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev. 2000. 19: 147-157. https://doi.org/10.1023/A:1026510130114
  9. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2000. 2: 727-739.
  10. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001. 61: 253-270. https://doi.org/10.1016/S0006-2952(00)00529-3
  11. Lund EL, Bastholm L, Kristjansen PE. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res. 2000. 6: 971-978.
  12. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009. 15: 220-231. https://doi.org/10.1016/j.ccr.2009.01.027
  13. Ryan PM. Therapeutic area crossroads: anti-angiogenesis. Nat Rev Drug Discov. 2008. 7: 115-116. https://doi.org/10.1038/nrd2507
  14. Tuma, Rabiya S. Taking Cues from Recent Blockbusters. Pharma DD. 2007. 2: 28-30.
  15. Willis LM, El-Remessy AB, Somanath PR, Deremer DL, Fagan SC. Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci. 2011. 120: 307-319. https://doi.org/10.1042/CS20100389